 
 
ANLON HEALTHCARE LIMITED 
CIN No.: U24230GJ2013PLC077543 
REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal M all, Kalawad Road, 
Rajkot-360005, Gujarat (INDIA) 
PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in 
November 19, 2025 
 
To, 
Listing Department, 
BSE Limited 
Phiroze Jeejeebhoy Towers, 
Dalal Street, 
Mumbai – 400 001 
Ref: BSE Scrip Code: 544497 
To, 
The National Stock Exchange of India 
Ltd. 
The Listing Department 
Exchange Plaza, 
Bandra – Kurla Complex, 
Mumbai – 400051, 
NSE Scrip Code: AHCL 
 
Subject: Investor Presentation – Q2/H1 - FY26 
 
Dear Sir/Madam, 
 
Pursuant to Regulation 30 of the Securiti es and Exchange Board of India (Listing 
Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the 
investor presentation, which is uploaded on our website as well. 
 
The same can be accessed through the link below: www.anlon.in.  
 
You are requested to take the above information on your record. 
 
Thanking You. 
 
Yours Faithfully, 
For ANLON HEALTHCARE LIMITED 
 
 
 
 
PUNITKUMAR RASADIA 
MANAGING DIRECTOR 
DIN: 06696258 
 
ANLON 
HEALTHCARE LIMITED
INVESTOR PRESENTATION Q2/H1 FY26
Key Performance Metrics:
Operations across 15 
countries
Global Presence:
21 Drug Master Files filed 
with global authorities
Regulatory Strength:
65 commercialized products, 
28 in pilot stage, and 49 under 
lab testing
Diverse Portfolio:
Served 125 customers 
till date (directly & 
Indrectly)
Customer Base:
400 MTPA installed production 
capacity
Manufacturing Capacity:
Over 7 years in manufacturing 
and sale of Pharma 
Intermediates & APIs
Industry Experience:
105 employees across 
operations
Workforce Strength:
Investor Presentation
About Us
Incorporated in 2013 and based in Rajkot, Gujarat, Anlon 
Healthcare Ltd. is a research-driven chemical manufacturer 
Engaged in manufacturing high-purity advanced pharmaceutical intermediates, 
used as key starting materials for APIs and active pharmaceutical ingredients 
(APIs), which serve as raw materials for finished dosage formulations
Among the few Indian manufacturers of Loxoprofen Sodium Dihydrate, 
Ketoprofen & Dexketoprofen Trometamol a key APIs used for pain and 
inflammation.
Strong global presence across 15 countries, serving pharmaceutical, 
nutraceutical, personal care, and animal health sectors
|
|
|
|
Investor Presentation
Regulatory Filings 
Brazilian Health Regulatory Agency (“ANVISA, Brazil”) for our API product namely, loxoprofen 
sodium dihydrate.
As on date, we have received approval for Drug Master File from and In process 
for Approval from the following
National Medical Products Administration, China (“NMPA, China”) for our API product namely, 
loxoprofen sodium dihydrate.
CEP Approcal from EDQM (Europe) for our API product namely, Ketoprofen
The Company has filed 21 DMFs with regulators across major international markets and is progressing DMF submissions for 
Ketoprofen in the USA and Dexketoprofen Trometamol in key European jurisdictions. The Approval is expected in a couple of years
Investor Presentation
Advancing Health with Purpose and Vision
With an approach to innovation 
that is compelling, inclusive and 
visionary, we seek to drive 
efficiency and productivity while 
delivering tangible results.
To harness the strength of 
technology and research into 
becoming a leading global 
pharmaceutical company that 
delivers maximum consumer 
satisfaction.
Investor Presentation
Building a Legacy of Growth
2013
Incorporated as Anlon Ventures 
Private Limited
2015
Renamed to Anlon Healthcare 
Private Limited
2019
Achieved ISO 9001:2015 
Certification
2018
Commenced commercial production 
of Pharma Intermediates and APIs
•  Exported first batch to South Korea
•  Received GMP certification from FDCA, Gujarat
•  Obtained Foreign Manufacturer Accreditation  
 from PMDA, Japan
2024
Received WHO-GMP 
certification for manufacturing 
facility
2021 2025
Got listed on BSE & 
NSE
Received Drug Master File (DMF) 
 Approval from Brazilian Health Regulatory Agency 
for Loxoprofen Sodium Dihydrate 
Converted to a public limited company and 
renamed Anlon Healthcare Limited
Investor Presentation
The Company’s manufacturing facility is located at Sadak Pipaliya, Rajkot (Gujarat), offering strategic connectivity through NH-27.
Comprises two dedicated blocks for Pharmaceutical Intermediates and APIs with a combined installed capacity of 400 MTPA.
Facility The facility is equipped with glass-lined and stainless-steel reactors, advanced filtration, centrifugation and 
drying systems includes 20L, 50L, 100L and 200L glass assemblies for process scale-up.
Capacity Utilization as on today is 84.41%.
State of the Art Manufacturing Facility 
Investor Presentation
4 dedicated labs with a total of 11 fume cupboards for advanced R&D work.
Driven by a dedicated and experienced team of 6 R&D professionals.
Equipped with an Autoclave for hydrogenation reactions and various advanced driers.
Facility includes 20L, 50L, 100L and 200L glass assemblies for process scale-up.
A separate, dedicated analytical development lab for effective evaluation of experimental results.
Powering Future Growth through Our R&D Engine 
Investor Presentation
• Pharmaceutical Intermediates serve as a key starting material or as an advance intermediate for manufacturing of APIs.
• Outlined below are some of our major Pharma Intermediates and their end-use applications:
Business Overview (1/3)
Pharmaceutical Intermediates
Ketonitrile: used for pain and 
inflammation management
3-(1-cyanoethyl)benzoic acid: Used 
in the synthesis of Ketoprofen, a 
pain-relief and anti-inflammatory 
drug
Loxoprofen Acid: used in synthesis of 
Loxoprofen Sodium Dihydrate which is 
used in pain-relief and anti-inflammatory 
drug
Guaiacol glycidyl ether: Guaiacol 
glycidyl ether is use as raw material of 
Ranolazine API.
Investor Presentation
Ketoprofen: a nonsteroidal anti-inflammatory 
agent with analgesic and antipyretic properties.
• Key components in medicines responsible for producing the desired therapeutic effect.
• Serve as the core raw materials for various finished dosage formulations such as tablets, capsules, syrups, and ointments. 
• Also used in Nutraceutical, Personal care and Veterinary products.
• Outlined below are some of the APIs and their end-use applications:
Business Portfolio (2/3)
Active Pharmaceutical Ingredients (APIs)
L-Carnitine Tartrate: is a diet 
supplement used to prevent and treat 
low blood levels of carnitine.
Dexketoprfen Trometamol: used for 
pain and inflammation
Ketoprofen Lysinate: Widely used NSAID for treating 
chronic inflammatory conditions such as osteoarthritis and 
rheumatoid arthritis, providing effective pain relief.
Investor Presentation
Business Overview (3/3)
• Provides end-to-end custom manufacturing solutions, encompassing process development to commercial-scale production, tailored to 
each customer’s specifications.
• Company’s technical team collaborates closely with clients to design, develop, and deliver products that meet precise technical, quality 
and regulatory standards.
• Each engagement ensures strict adherence to specifications, sample validation and customer audits for consistent quality and compliance.
• The Company is currently developing 3 molecules for 2 global innovator companies as a CDMO Project
Custom Manufacturing
Customer Inquiry Response with
feasiblity Study Signing NDA / CDA P r o c e s s  Ev a l u a t i o n
Pilot-scale Trial
Sample Approval
Customer Validation
Order Placement
* NDA is signed only upon specific request from the customers
Sampleing Costing Testeing and Trails
Raw Material 
Procurement
Commercial
Production
Investor Presentation
Application of Core APIs
Investor Presentation
3 Core APIs across 5 Therapeutic areas
Pain and Inflammation 
Osteoarthritis
Rheumatoid arthritis
Lower Back Pain
Antipyretic
Investor Presentation
Segment wise- Revenue Contribution
58.13%
35.70%
6.16%
FY-25
API Pharmaceutical Intermeddiate Neutraceuticals
77.61%
7.37%
14.58%
FY-24
API Neutraceuticals Pharmaceutical Intermeddiate
Investor Presentation
Segment wise- Revenue Contribution 
As on H1 F26 V/s & Q2 FY26 V/s Q2 FY25
64.52%
26.67%
8.81%
H1 FY-25
API Pharmaceutical Intermeddiate Neutraceutical
76.22%
10.24%
13.54%
Q2 FY-25
API Pharmaceutical Intermeddiate Neutraceutical
27.21%
70.36%
2.31% H1 FY-26
API Pharmaceutical Intermeddiate Neutraceutical
30.42%
68.40%
1.13% Q2 FY-26
API Pharmaceutical Intermeddiate Neutraceutical
Investor Presentation
Segmental Wise Revenue from Top 5 & Top 10 Customers 
Q2 FY26 H1 FY26 
96.30%
83.42%
100.00%
99.90%
99.67%
100.00%
API Pharmaceutical
Intermeddiate
Neutraceutical
Top 5 Customers Top 10 Customers
78.85% 77.62%
100.00%
92.67% 99.16%
100.00%
API Pharmaceutical
Intermeddiate
Neutraceutical
Top 5 Customers Top 10 Customers
Investor Presentation
A diversified portfolio of 65 
commercialized, 28 pilot and 49 
lab-stage products.
Strong Product 
Portfolio & Scalable 
Business
High-compliance manufacturing with strong 
DMF/GMP credentials and 33 approvals, with 
zero order cancellations reflecting customer 
confidence.
High Entry Barriers and 
Strong Quality Systems
Led by experienced promoters 
and a qualified management 
team with 10+ years of industry 
experience across key functions.
Strong Promoters 
& Experienced 
Management
4 in-house R&D centers with 
QA/QC support driving product 
development, quality, and 
scalable compliance.
In-house R&D & QA 
/ QC For Quality 
Control
Sustainable Competitive Edge 
Investor Presentation
Strategic Initiatives 
Expand Customer 
Base and Wallet Share
Expanding customer wallet share and global reach 
through strong relationships, cross-selling, and 
China+1–driven demand.
Portfolio Diversification 
and Expansion
Expanded portfolio from 10 products in FY2018 
to 65 in FY2025, with continued diversification 
into high-growth, high-margin segments.
Improve cost management 
& operational efficiencies
Driving profitability through cost discipline, 
efficiency gains, and a shift to high-value 
products.
New Product Development and 
DMF Filing for Regulatory:
The Company is targeting 10–15 global DMF 
filings in the next 5 years to expand its 
regulatory footprint.
Investor Presentation
CONTENT
Industry Overview
Investor Presentation
• The global pharmaceutical market size will grow from USD 1.77 trillion in 2025 to nearly USD 3.03 trillion by 2034, 
expanding at a strong CAGR of 6.15% from 2025 to 2034. 
• North America held the largest market share of 42% in 2024, while the Asia Pacific is projected to witness the 
fastest growth during the forecast period.
Following are the latest trends in the Global Pharmaceuticals Market:
AI and Machine Learning in Drug Discovery – Transforming R&D eficiency through predictive 
algorithms, reducing time and cost for new drug development.
Expansion of mRNA and Gene Therapies – Strong pipeline growth in next-generation therapies 
addressing cancer, rare, and infectious diseases.
Biosimilars and Biologics Growth – Rising global demand for biologics and cost-effective 
biosimilars driving significant market expansion.
Following are the latest trends in the Global Pharmaceuticals Market :
Global Pharmaceuticals Industry
1.77
3.03
2025 2034
Global Pharmaceuticals 
Industry ( in USD trillion)
Source: Globenewswire
Investor Presentation
Indian Pharmaceutical market stood at USD $55 billion in 2025 and is expected to grow 
to USD $120-130 billion by 2030.
PLI scheme: USD $2.04 billion outlay to boost manufacturing, investment and product 
diversification.
Strengthening of Pharmaceutical Industry (SPI):USD $60.6 million to support pharma clusters 
and MSMEs in productivity, quality and sustainability
India has the largest number of USFDA-compliant plants outside the US and over 2,000 WHO-
GMP approved facilities, exporting to 150+ countries.
Up to 100% FDI allowed via automatic route for Greenfield pharma projects; up to 74% for 
Brownfield via automatic route, beyond that with government approval.
The Drugs & Pharmaceuticals sector received FDI inflow of US$ 24.62 billion from April 2000-
June 2025.
Economic Drivers:
Indian Pharmaceutical Industry
Government Support:
55
130
2025 2034
Global Pharmaceuticals 
Industry ( in USD Billion)
Source: IBEF
Investor Presentation
Growth Drivers:
• Global API market stood at USD $217.2 billion in 2024 and is expected to grow to USD $231.95 
billion by 2025.
• It is further projected to grow at USD $418.96 billion by 2034 expanding at a CAGR of 6.79% from 
2025 to 2034.
• USA plays an active role in API space by contributing over 83% of North America’s total demand 
• Over 65% of drug approvals originate from USA
Surging demand for Generic Drugs
Technological advancements in biologics and synthesis
Rising prevalence in chronic diseases
Global API Industry
217.2
418.8
2024 2034
Global API Industry ( in 
USD Billion)
Source: Globalgrowthinsights
Investor Presentation
India's Active Pharmaceutical Ingredients (APIs) market is expected to expand to reach 
USD 22 billion by 2030 at a CAGR of 8.3%.
Growing domestic and export demand for generics and bulk drug. 
Push for self reliance import substitution
Competitive cost base and manufacturing ecosystem
Growth Drivers:
The PLI scheme for pharmaceutical/Bulk-drugs/API manufacturing: aimed at promoting domestic production of key APIs 
and key starting materials. 
Setting up “bulk drug parks” with infrastructure support to enable large-scale API manufacturing and reduce dependence 
on imports.
Focus on reducing dependence on imports (especially from China) of APIs and key starting materials (KSMs) and enhancing 
global competitiveness of Indian API producers.
Government Initiatives:
Indian API Industry
Investor Presentation
Particulars (In INR crs) FY24 FY25
Revenues 66.58 120.29
Other Income 0.11 0.17
Total Income 66.69 120.46
Raw Material Expenses 33.66 74.59
Employee Benefits Expense 4.78 4.88
Other Expenses 12.68 8.61
Total Expenditure 51.12 88.08
EBITDA 15.57 32.38
EBIDTA Margin (%) 23.35% 26.88%
Finance Costs 3.93 3.72
Depreciation & Amortisation Expenses 1.89 1.77
PBT 9.75 26.89
Tax 0.09 6.37
PAT 9.66 20.52
PAT Margin (%) 14.48% 17.03%
Total Comprehensive Income 0.00 0.00
EPS (In INR) 6.68 6.37
INCOME STATEMENT
Investor Presentation
Half Yearly Income Statement
Particulars (In INR crs) H1FY25 H1FY26
Revenues 62.00 85.49
Other Income 0.11 0.04
Total Income 62.11 85.53
Raw Material Expenses 41.32 57.18
Employee Benefits Expense 2.41 2.29
Other Expenses 3.83 6.06
Total Expenditure 47.56 65.52
EBITDA 14.55 20.01
EBIDTA Margin (%) 23.43% 23.39%
Finance Costs 1.91 1.68
Depreciation & Amortisation Expenses 0.95 0.88
PBT 11.69 17.45
Tax 5.33 4.59
PAT 6.36 12.86
PAT Margin (%) 10.23% 15.04%
Total Comprehensive Income 0.00 0.00
EPS (In INR) 2.56 3.07
Investor Presentation
INCOME STATEMENT
Particulars (In INR crs) Q2FY25 Q2FY26
Revenues 24.17 52.20
Other Income 0.05 0.03
Total Income 24.21 52.23
Raw Material Expenses 13.59 32.96
Employee Benefits Expense 1.25 1.06
Other Expenses 1.81 4.44
Total Expenditure 16.64 38.46
EBITDA 7.57 13.77
EBIDTA Margin (%) 31.26% 26.36%
Finance Costs 0.93 0.87
Depreciation & Amortisation Expenses 0.47 0.45
PBT 6.16 12.45
Tax 3.57 3.13
PAT 2.59 9.32
PAT Margin (%) 10.71% 17.84%
Total Comprehensive Income 0.00 0.00
EPS (In INR) 0.41 2.22
Investor Presentation
BALANCE SHEET
Equities & Liabilities (In INR Crs) FY24 FY25 H1FY26
Equity 16.00 39.85 53.15
Other Equity 5.03 40.57 161.16
Net Worth 21.03 80.42 214.32
Non Current Liabilities
Long-Term Borrowings 54.25 38.36 30.86
Deferred Tax Liabilities 2.40 2.23 2.17
Long Term Provision 0.22 0.24 0.24
Total Non Current Liabilities 56.87 40.83 33.28
Current Liabilities
Short-Term Borrowings 20.32 19.99 26.97
Trade Payables 19.99 19.64 16.56
Short Term Provisions 2.17 8.64 13.25
Other Current Liabilities 7.62 11.78 5.11
Total Current Liabilities 50.10 60.05 61.89
Total Liabilities 128.00 181.30 309.48
Assets FY24 FY25 H1FY26
Non Current Assets
Fixed Assets 27.30 22.82 21.97
Deferred Tax Assets 0.00 0.00 0.00
Other Non Current Assets 0.00 0.00 0.00
Total Non Current Assets 27.30 22.82 21.97
Current Assets
Cash & Bank Balance 3.12 1.45 24.94
Inventories 41.71 50.26 56.53
Trade receivables 38.73 75.00 107.45
Short-Term Loans and Advances 1.39 2.28 2.37
Other Current Assets 15.75 28.58 96.22
Total Current Assets 100.70 158.48 287.51
Total Assets 128.00 181.30 309.48
Investor Presentation
KEY FINANCIAL METRICS (1/3)
66.69
120.46
FY24 FY25
Total Income (INR Crs)
15.57
32.38
23.35%
26.88%
21. 00%
22. 00%
23. 00%
24. 00%
25. 00%
26. 00%
27. 00%
28. 00%
0.0 0
5.0 0
10. 00
15. 00
20. 00
25. 00
30. 00
35. 00
FY24 FY25
EBITDA (INR Cr) & EBITDA Margins (%)
9.66
20.52
14.48%
17.03%
13. 00%
13. 50%
14. 00%
14. 50%
15. 00%
15. 50%
16. 00%
16. 50%
17. 00%
17. 50%
0.0 0
5.0 0
10. 00
15. 00
20. 00
25. 00
FY24 FY25
PAT (INR Cr) & PAT Margins (%)
21.03
80.42
FY24 FY25
Networth (INR In Cr)
3.82
0.82
FY24 FY25
Net Debt/ Equity (x)
13.38%
20.82%
45.92%
25.51%
FY24 FY25
ROCE(%) & ROE(%)
ROCE (%) ROE (%)
Investor Presentation
KEY FINANCIAL METRICS (2/3)
24.21
52.23
Q2FY25 Q2FY26
Total Income (INR Crs)
7.57
13.77
0.0 0
2.0 0
4.0 0
6.0 0
8.0 0
10. 00
12. 00
14. 00
16. 00
Q2FY25 Q2FY26
EBITDA (INR Cr) 
2.59
9.32
0.0 0
1.0 0
2.0 0
3.0 0
4.0 0
5.0 0
6.0 0
7.0 0
8.0 0
9.0 0
10. 00
Q2FY25 Q2FY26
PAT (INR Cr) 
Investor Presentation
KEY FINANCIAL METRICS (3/3)
62.11
85.53
H1FY25 H1FY26
Total Income (INR Crs)
14.55
20.01
0.0 0
5.0 0
10. 00
15. 00
20. 00
25. 00
H1FY25 H1FY26
EBITDA (INR Cr) 
6.36
12.86
0.0 0
2.0 0
4.0 0
6.0 0
8.0 0
10. 00
12. 00
14. 00
H1FY25 H1FY26
PAT (INR Cr) 
Investor Presentation
STOCK DATA & SHAREHOLDING PATTERN
BSE:
Share Price ₹ 146.00
Market Capitalization ₹ Cr 776.01
No. of Share Outstanding 5,31,51,500
Face Value ₹ 10.00
52 Week High ₹ 149.50
52 Week Low ₹ 86.98
Shareholding Pattern (%)
As on 11-11-2025 As on 30-09-2025
Source: BSE
52.68
47.32
Promoter & Promoter
Group
Public
Investor Presentation
Brief Profile of Board of Directors 
He has been associated with the Company since August 2024 
and is a retired banking professional. 
He previously served as Deputy General Manager at Corporation 
Bank and brings over 20 years of experience in the banking 
sector, offering valuable financial and strategic insights to the 
Board.
Mr. Meet Atulkumar Vachhani
( Whole-time Executive Director )
He holds a Master’s degree in Industrial Chemistry from Sir P. P. 
Institute of Science, Bhavnagar, and has over 11 years of experience 
in the pharmaceutical industry.
He possesses strong expertise in sourcing and supplying specialty 
chemicals, intermediates, APIs, and bulk drugs. He leads the 
Company’s strategic direction, operations, and growth initiatives. 
Mr. Punitkumar Rasadia 
(Chairman & Managing Director)
She has been associated with the Company since July 2024. She 
holds a Master’s degree in Chemistry and a Diploma in Pharmacy 
from Saurashtra University. 
She provides strategic guidance and supports key business 
initiatives of the Company.
Mrs. Mamta Punitkumar Rasadia
(Non-Executive Director)
He is a founding Promoter and has been associated with the 
Company since its inception. With over 11 years of experience in the 
pharmaceutical industry, he oversees administration, strategy, 
finance, and sales. 
He plays a key role in driving operational excellence, business 
growth, and product innovation
He has been associated with the Company since August 2024 and 
holds a Bachelor’s degree in Science from Sardar Patel University. 
With over 20 years of experience in the pharmaceuticals, 
cosmeceutical, and nutraceutical industries, he provides valuable 
industry insight and strategic guidance to the Board
He has been associated with the Company since August 2024 
and is a qualified Chartered Accountant from the Institute of 
Chartered Accountants of India (ICAI). 
With over 25 years of experience in accountancy, he brings 
strong financial acumen and governance expertise to the Board.
Mr. Kannepalli Krishna Murty
(Non-Executive Independent Director)
Shailesh Kantilal Thakkar 
( Non-executive Independent Director )
Anandbhai Natwerlal Katkoria
( Non-Executive Non-Independent Director)

Strategic Allocation of IPO Proceeds
Strengthen Balance Sheet (₹5.00 Cr)
Strategically repay or prepay outstanding secured borrowings to 
de-risk our financial profile, reduce finance costs, and improve 
our debt-equity ratio.
Fund Capacity Expansion (₹30.71 Cr 
Allocate capital for our 'Proposed Expansion' to establish a new large-
scale manufacturing plant of 700 MTPA near Pipaliya 
(Rajkot),significantly increasing our production capacity to 1,100 MTPA 
and enhancing operational efficiencies.
Augment Working Capital (₹43.15 Cr)
Fund our increasing working capital requirements to ensure operational 
agility and support our anticipated business growth.
General Corporate Purposes 
Address general corporate expenses and achieve the benefits of a 
public listing, such as creating a liquid market for our shares and 
enhancing brand visibility.
Investor Presentation
Future Outlook 
Growth Pillars for 
FY26 and beyond
• Compliance-Hardened, Globally Ready Platform Post-ANVISA clearance with zero observations establishes a next-generation 
compliance foundation for global scale-up.
• Positions Anlon as a future-ready, audit-resilient partner for regulated markets across LATAM, Europe and emerging regulated 
ecosystems.
• China+1 Strategy Activation Building new, high-throughput, globally compliant capacity designed to compete head-on with 
entrenched low-cost API suppliers.
• Strategically placed to capture the next wave of pharma outsourcing as global innovators accelerate diversification beyond 
China.
• Planned to launch 7 APIs for new therapeutic categories in FY 2026-27
• Diversifying into Industrial and Fine Chemicals to capture new business opportunities
• The CDMO project is currently in the validation phase and is on track for commercialization by Q3 FY 27, positioning us for 
next-generation growth.
• Poised to file 3–5 DMFs during FY 2026–27.
• Poised to achieve a 3-year revenue CAGR of 30%, accompanied by sustainable and gradual improvement in 
EBITDA margins
Investor Presentation
• The Company has developed 20 nutraceutical products supplied to customers across India and global markets.
• India Nutraceuticals Market was valued at USD 6.11 billion in 2024 and is anticipated to reach USD 11.55 billion by 2030, with a CAGR of 
11.39 % during 2025-2030. 
• India's large and diverse population is becoming increasingly health-conscious, driving the demand for nutraceutical products.
• Source: Research & Markets
Nutraceuticals
• The India beauty and personal care market size was valued at USD 28 Billion in 2024. Looking forward it is estimated to reach USD 48.3 Billion by 2033, 
exhibiting a CAGR of 5.60% during 2025-2033.
• A diversified product range, rising demand for natural and organic products, and growing e-commerce penetration have expanded India’s beauty and 
personal care market, driving higher demand for APIs used in personal care formulations. 
• Source: IMARC
Personal Care
• The India veterinary medicine market size was estimated at USD 1.73 billion in 2024 and is projected to reach USD 4.17 billion by 2033, growing at a 
CAGR of 10.23% from 2025 to 2033.
• This market is experiencing growth due to rising awareness about the importance of animal healthcare, a growing number of animal disease outbreaks 
and increasing demand for animal-derived protein.
• Source: Grandview research
Veterinary (Animal Health)
Cross Industry Market Opportunity
Investor Presentation
02
Marks a strategy to enter in 
Industrial and Fine chemicals 
business
04
Target customers include global 
health organizations, governments, 
and leading Pharmaceutical and 
Innovator companie.
These APIs & Intermediate 
combination to regulatory market will 
boost the revenue for FY26.
03
Represents a clear, near-term 
revenue catalyst for FY26 and 
beyond.
05
Developed two new APIs: Artemether and 
Lumefantrine, slated for commercial 
launch by November 2025.
01
Future Growth Roadmap for APIs
Investor Presentation
THANK YOU
Confideleap Partners
103-8, Lodha Eternis, MIDC, Andheri East, 
Mumbai 400093 Maharashtra, India.
Phone: +91 85911 45959
Email: info@confideleap.com 
Website: www.confideleap.com 
Anlon Healthcare Limited
Registered Office101/102-Silver Coin 
Complex, Opp. Crystal Mall, Kalawad 
Road,Rajkot 360005, Gujarat (INDIA)
Phone: +91 281-2561 340, +91 281-2562 538/39
Email: info@anlonhealthcare.com
Website: https://www.anlon.in/
Investor Presentation

